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abstract
We extend the ARE method proposed in Gómez and Lagakos (2013) devised to decide which primary
endpoint to choose when comparing two treatments in a randomized clinical trial. The ARE method
is based on the Asymptotic Relative Efficiency (ARE) between two logrank tests to compare two treat-
ments: one is based on a relevant endpoint E1 while the other is based on a composite endpoint
E∗ = E1 ∪ E2, where E2 is an additional endpoint. The ARE depends, besides some intuitive parame-
ters, on the joint law of the times T1 and T2 from randomization to E1 and E2, respectively. Gómez and
Lagakos (2013) characterize this joint law by means of Frank’s copula. In our work, several families of
copulas can be chosen for the bivariate survival function of (T1, T2) so that different dependence struc-
tures between T1 and T2 are feasible. We motivate the problem and show how to apply the method
through a real cardiovascular clinical trial. We explore the influence of the copula chosen into the ARE
value by means of a simulation study. We conclude that the recommendation on whether or not to use
the composite endpoint as the primary endpoint for the investigation is, almost always, independent
of the copula chosen.
Key words: Asymptotic relative efficiency; Composite endpoint; Copulas; Logrank; Randomized clin-
ical trial
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1 introduction
When comparing two treatment groups by means of a randomized clinical trial (RCT), the choice of
the primary endpoint is crucial. It is often the case in which several relevant events might be chosen
as the primary endpoint for the analysis and the decision on which one to choose might be difficult.
Sometimes, the event with the greatest clinical importance is the chosen one while the other events
are assessed using secondary analysis. In other situations, two or more events are of comparable
importance and, in those cases, it is common to use the union of them as the primary endpoint. In
general, the decision on which endpoint to use is, among other criteria, based on the prior knowledge
of the frequency of observing the “candidate” events as well as on the anticipated effect that the
treatment could have on each event.
Several authors have discussed the advantages and disadvantages of using a composite endpoint
from a clinical perspective (Ferreira-González et al., 2007b; Gómez, 2011; Freemantle et al., 2003; Mon-
tori et al., 2007; Ferreira-González et al., 2007a). One of the main clinical arguments is that the com-
posite endpoint could capture the net benefit of the intervention, avoiding the need to choose a single
main endpoint when different endpoints are of equal importance. From a statistical point of view,
two main arguments are: i) a composite endpoint reduces the multiplicity problem that may occur
if different endpoints are used separately; and ii) a larger number of events will be observed when
using a composite endpoint than for any relevant event alone. However, as it is shown in Gómez and
Lagakos (2013), a larger number of events would not necessarily imply a more powerful test for treat-
ment efficacy. Moreover, the use of a composite endpoint could entail certain difficulties such as how
to interpret the results of a trial when the primary endpoint is composed of events of different clinical
importance. It is also important to keep in mind that a significant treatment effect on the composite
endpoint does not necessarily imply an effect on each of the components (Gómez, 2011).
Gómez and Lagakos (2013) have provided a statistical methodology to derive efficiency guidelines
for deciding whether to expand a study’s primary relevant endpoint E1 to the composite E∗ of E1
and E2, where E2 is some additional endpoint. This methodology has already been applied to derive
recommendations for the choice of the primary endpoint in cardiovascular randomized clinical trials
(Gómez et al., 2014). The method they propose is based on the Asymptotic Relative Efficiency (ARE)
of a logrank test for comparing treatment groups with respect to the time T1 from randomization to
E1 versus the time T∗ from randomization to E∗. For the computation of the ARE, and among other
things to be discussed below, the law of (T1, T2) is derived binding the marginals distributions of T1
and T2, the time from randomization to E2, by means of Frank copula.
The choice of the copula is a crucial step in the ARE computations. There are some statistical
procedures available to decide which copula fits better existing data (see for example Genest et al.
(2009)). However, the methodology developed by Gómez and Lagakos (2013) provides a tool to choose
the primary endpoint of a RCT during its design, when the data is still not available and it is not
possible to apply such procedures. The recommendation on whether to base the RCT on a relevant
endpoint E1 or use the composite E∗ might heavily depend on this choice. Since different families
of copulas might exhibit substantially different dependence structures, even with similar degrees of
dependence, it is important to consider other copulas in the construction of the bivariate survival
function of (T1, T2) and to explore the impact that this choice might have.
The main aim of this paper is twofold: on one hand, it extends the ARE method to other families of
copulas, allowing different joint behaviors between T1 and T2; on the other, it explores the influence of
the copula chosen into the ARE values. Furthermore, it examines the impact that a copula has on the
recommendation for the primary endpoint for the RCT. The remainder of this paper is organized as
follows. In Section 2, we extend the ARE method to families of copulas other than Frank and introduce
a real clinical trial to motivate the problem and to show how to use this method. In Section 3, we study
the sensitivity of the ARE values to the choice of the copula. Simulated scenarios have been set up
and the ARE values have been compared using different copulas. Finally, we make the concluding
remarks in Section 4.
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2 the asymptotic relative efficiency (are) method
This section extends the ARE method to families of copulas other than Frank. We start with the
description of the ARE method, continue with a subsection devoted to the construction of joint survival
functions given their univariate marginals via a copula model where we introduce and compare Frank,
Gumbel, Clayton, Farlie-Gumbel-Morgenstern (FGM), Normal, t, Plackett, Galambos, Hüsler-Reiss,
Tawn and t-EV copulas, with special emphasis to the first three. A third subsection is dedicated to
how to compute the ARE values using R. This section ends with a case study concerning a randomized
clinical trial designed to test the effect of the antioxidant succinobucol on cardiovascular outcomes in
patients with recent acute coronary syndrome.
2.1 Notation and summary of the ARE method
Consider a two-arm randomized study with assignment to an active (X = 1) or control treatment
(X = 0), for example new treatment versus standard of care or placebo. Let us assume that both the
relevant endpoint E1 and the composite endpoint E∗ = E1 ∪E2 could answer satisfactorily the study’s
primary clinical question. Denote by T∗ = min{T1, T2} the time from randomization to E∗ and assume
that T1 and T2 are absolutely continuous so that ties cannot occur. Gómez and Lagakos assume in the
ARE method that the end-of-study censoring at time τ is the only non-informative censoring cause
and, without loss of generality, take τ = 1 for computational purposes. They also assumed that this
censoring is identical across treatment groups.
Let Z (similarly Z∗) be the logrank test to compare the two treatment groups with respect to the
relevant endpoint E1 (similarly with respect to the composite endpoint E∗). Denote by ARE(Z∗,Z) the
Asymptotic Relative Efficiency of Z∗ versus Z. Efficiency calculations are evaluated on the basis of
a sequence of contiguous alternatives to the null hypothesis of no treatment effect, and based on the
following assumptions: (i) the correlation between T1 and T2 is the same for both treatment groups;
(ii) the hazards for T1 and T2 between the two treatment groups are proportional. For i = 1, 2, let
λ
(j)
i (t) (j = 0, 1) be the hazard function of endpoint Ti for treatment group j and denote by HRi =
λ
(1)
i (t)/λ
(0)
i (t) the hazard ratio; and (iii) Weibull distributions have been chosen as the law for T1 and
T2 with scale parameters b
(j)
1 and b
(j)
2 for groups j = 0, 1 and shape parameters β1 and β2 chosen
equal for both groups so that the proportionality of the hazards holds.
Based on the above assumptions, and assuming that the additional endpoint does not contain a
terminating event among its components (Censoring cases 1 and 3 in Gómez and Lagakos paper), the
expression of the ARE value is as follows
ARE(Z∗,Z) =
(∫1
0 log
(
λ
(1)
∗ (t;θ)
λ
(0)
∗ (t;θ)
)
f
(0)
∗ (t; θ)dt
)2
(log HR1)
2 (
∫1
0 f
(0)
∗ (t; θ)dt)(
∫1
0 f
(0)
1 (t)dt)
(1)
where f(0)1 (t) and f
(0)
∗ (t; θ) are the density functions of T1 and T∗ in group 0, λ
(0)
∗ (t; θ) and λ
(1)
∗ (t; θ)
are the hazard functions of T∗ in group 0 and group 1, respectively, and θ is a parameter, introduced
in Section 2.2, that measures the dependence between T1 and T2 in either group.
In order to get a meaningful expression for the ARE given in (1) in terms of interpretable and
anticipatable parameters, a relationship between them and f(0)1 (t), f
(0)
∗ (t; θ), λ
(0)
∗ (t; θ) and λ
(1)
∗ (t; θ) is
sought. Gómez and Lagakos use Frank’s copula to bind the marginals of T1 and T2, and, from there,
obtain the law of T∗, and, consequently, expressions for the density and the hazard functions.
After choosing a copula, the ARE value depends uniquely on the survival functions of T1 and
T2 and on the dependence parameter θ. It can be shown that θ is in one-to-one relationship with
Spearman’s rank correlation coefficient ρ, and that the marginals can be identified from the following
set of parameters: the frequencies p1 and p2 of observing the endpoints E1 and E2 in treatment group
0, the relative treatment effects on E1 and E2 given by the hazard ratios HR1 and HR2, and, the shape
parameters β1 and β2 of the Weibull distributions used as the law for T1 and T2, respectively.
Given these set of parameters, one might compute the ARE value and decide the most efficient
endpoint between E1 (ARE 6 1) and E∗ (ARE > 1). We illustrate the ARE method assuming that the
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Figure 1: ARE values calculated using Frank copula for parameters p1 = 0.2, p2 = 0.1, HR1 = 0.8 and β1 = β2 =
1 and for different values of HR2 and ρ.
probability of observing E1 and E2 is, respectively, p1 = 0.2 and p2 = 0.1 and that the expected effect
of the treatment on E1, given by the hazard ratio, is set to HR1 = 0.8. Figure 1 plots the ARE values for
different values of HR2, the effect of the treatment on E2; different values of ρ, the correlation between
T1 and T2 in group 0; and for the particular case in which the hazards are constant (β1 = β2 = 1). This
figure provides an extra tool to decide between E1 and E∗, even when the values of HR2 or ρ are only
known within a range.
It is worth noting that the above set of assumptions established in Gómez and Lagakos are often
assumed when designing a clinical trial. Furthermore, the set of parameters required by the ARE
method corresponds to those needed for the computation of the sample size in a trial. Henceforth,
neither the assumptions nor the needed anticipated values could be considered as a limitation in the
design of this type of studies.
2.2 Extension of the ARE method to different copulas
Copulas can be used to define different dependence structures for pairs of random variables (Trivedi
and Zimmer, 2007). In fact, multivariate distributions with similar degrees of dependence might ex-
hibit substantially different dependence structures depending on the copula chosen. The computation
of the ARE depends on the joint law between T1 and T2, and hence, on the copula chosen.
Given a bivariate copula C, marginal survival functions S(j)1 (t1) and S
(j)
2 (t2) of T1 and T2, respec-
tively, in group j (j = 0, 1), and a dependence parameter θ between T1 and T2, the joint survival
function of (T1, T2) is given by
S
(j)
(1,2)(t1, t2; θ) = S
(j)
1 (t1) + S
(j)
2 (t2) − 1+C(1− S
(j)
1 (t1), 1− S
(j)
2 (t2); θ), (2)
where C, function from I2 to I = [0, 1], is a two-dimensional copula that binds together 1− S(j)1 (t1)
and 1− S(j)2 (t2) as follows:
Pr{T1 6 t1, T2 6 t2|group j} = C(1− S(j)1 (t1), 1− S
(j)
2 (t2); θ).
Note here that the dependence parameter θ has been taken equal for both treatment groups as in
Gómez and Lagakos.
The survival function of T∗ = min{T1, T2}, namely S
(j)
∗ (t; θ) = Pr{T∗ > t; θ|X = j}, for group j is
given by
S
(j)
∗ (t; θ) = Pr{T1 > t, T2 > t; θ|X = j} = S
(j)
(1,2)(t, t; θ),
the asymptotic relative efficiency (are) method 6
and can be obtained from (2) after choosing a copula. In particular, it follows that the survival, density
and hazard function for the composite endpoint T∗ in terms of the copulas are given by
S
(j)
∗ (t; θ) = S
(j)
1 (t) + S
(j)
2 (t) − 1+C(1− S
(j)
1 (t), 1− S
(j)
2 (t); θ) (3)
f
(j)
∗ (t; θ) = f
(j)
1 (t) + f
(j)
2 (t) −
∂
∂t
C(1− S
(j)
1 (t), 1− S
(j)
2 (t); θ) (4)
λ
(j)
∗ (t; θ) =
f
(j)
∗ (t; θ)
S
(j)
∗ (t; θ)
.
In our work, we extend the ARE method to the following 11 families of copulas: Frank, Gumbel,
Clayton, Farlie-Gumbel-Morgenstern (FGM), Normal, t, Plackett, Galambos, Hüsler-Reiss, Tawn and t-
EV. Table 1 shows the expression for each of these copulas. Since Frank, Gumbel and Clayton copulas
are the copula families more often used, we present with greater detail in 4 their expressions and
discuss the type of dependencies that these 3 families might exhibit, as well as the specific expression
of the survival and density functions of T∗.
Table 1: Expression C(u, v; θ) and the domain of the dependence parameter θ of the following copulas: Frank,
Gumbel, Clayton, Farlie-Gumbel-Morgenstern (FGM), Normal, t, Plackett, Galambos, Hüsler-Reiss,
Tawn and t-EV.
Copula type C(u, v; θ) θ-domain
Frank −1θ log
(
1+
(e−θu−1)(e−θv−1)
e−θ−1
)
(−∞,∞)
Gumbel exp
(
−[(− log(u))θ + (− log(v))θ]1/θ
)
[1,∞)
Clayton max{[u−θ + v−θ − 1]−1/θ, 0} [−1,∞)\{0}
FGM uv+ θuv(1− u)(1− v) [−1, 1]
Normal Φθ(Φ−1(u),Φ−1(v)) [−1, 1]
t t`, ˚ (t−1˚ (u), t
−1
˚ (v)) [−1, 1]
Plackett [1+(θ−1)(u+v)]−
√
[1+(θ−1)(u+v)]2−4uvθ(θ−1)
2(θ−1) (0,∞)
Galambos uv exp[{(log(u))−θ + (log(v))−θ}−1/θ] [0,∞)
Hüsler-Reiss exp{− log(u)Φ[ 1θ +
1
2θ log(
log(u)
log(v) )] − log(v)Φ[
1
θ +
1
2θ log(
log(v)
log(u) )]} [0,∞)
Tawn uv exp
(
−θ
log(u) log(v)
log(uv)
)
[0, 1]
t-EV exp
(
log(uv)Aθ,ν
log(u)
log(v)
)
[0, 1]
Φθ and t`, ˚ with ν degrees of freedom denote the standard bivariate normal and Student’s t
joint distribution function with correlation coefficient θ, respectively. Φ and t ˚ with ν degrees
of freedom denote the standard normal and Student’s t distribution function, respectively.
Aθ,ν is the Pickands dependence function based in the bivariate Student’s t`, ˚ . In this study,
the degrees of freedom have been set to ν = 4.
2.3 Computation of the ARE values using R
As seen in Section 2.1, Gómez and Lagakos relate the expression of the ARE to the following in-
terpretable parameters: (p1,p2, HR1, HR2, ρ,β1,β2), representing, respectively, the frequencies of ob-
serving the endpoints E1 and E2 in treatment group 0, the relative treatment effects on E1 and E2,
Spearman’s rank correlation between T1 and T2 in either group and the shape parameters of the
Weibull marginal survivals.
Using the R-package copula (Hofert et al., 2014; Yan, 2007; Kojadinovic and Yan, 2010; Hofert and
Maechler, 2011), we have written a program to compute the ARE values for a given copula chosen
among the 11 families introduced in Section 2.2 (copula), taking into account whether E1 and E2
contain a terminating event (case) and as a function of the above parameters:
ARE(rho,beta1,beta2,p1,p2,HR1,HR2, case, copula)
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This function is easy to use and allows the computation of the ARE value for a large amount of
simulated situations. The body of this function can be divided into three parts: (i) the first one takes
care of selecting the copula that is going to be used and computes the copula dependence parameter
θ for a given Spearman’s correlation ρ; (ii) the second part of the algorithm builds the marginal
distribution functions from the anticipated values (p1,p2, HR1, HR2,β1,β2); and (iii) the third part of
the program computes the value of the ARE for the chosen copula and the marginal distributions set
in the first two parts of the function.
2.4 A case study: Treating patients after an acute coronary syndrome with succinobucol
A case study (Tardif et al., 2008) is used to illustrate how to use the ARE method, to show how to
select the primary endpoint and to explore how sensitive are the results to the choice of a particular
copula.
A randomized clinical trial (Tardif et al., 2008) was designed to test the effect of the antioxidant suc-
cinobucol on cardiovascular outcomes in patients with recent acute coronary syndrome. The primary
efficacy endpoint, denoted by E∗, was the union of E1 and E2, where E1 was the first occurrence be-
tween cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction and non-fatal
stroke; and E2 was the first occurrence of hospitalization due to either unstable angina with objective
evidence of ischaemia or coronary revascularisation. The trial did not show statistically significant
differences in terms of the primary composite endpoint E∗ obtaining a hazard ratio HR∗ = 1.00 (95%
confidence interval (CI): 0.89− 1.13, p-value (p)=0.96). However, secondary analysis did show a ben-
eficial effect of succinobucol in terms of E1 with hazard ratio HR1 = 0.81 (95% CI of 0.68− 0.98, p
=0.029). In this trial, there were many more hospitalizations (E2) than E1 events, but, since the number
of hospitalizations were similar in both treatment groups, the effect on the composite endpoint E∗ was
diluted. This is an instance of how adding an event E2 to a relevant one E1 can lead to the disappear-
ance of the statistically significant benefit of the active treatment that would have been found on the
relevant outcome (E1).
We examine the ARE value of the alternative treatment with succinobucol versus placebo for the
reported values in the trial (p1 = 0.082, p2 = 0.09, HR1 = 0.81) and for different values of HR2
ranging from 0.3 to 0.95 (actual value in the trial was 1.05), for different shapes of the time-to-event
distributions (nine combinations including increasing, constant and decreasing hazard functions for T1
and T2), for correlation values ranging from 0.15 to 0.75 and for the 11 copulas presented in Section 2.2.
A total of 504 scenarios for different values of β1, β2, ρ and HR2 and for fixed p1 = 0.082, p2 = 0.09
and HR1 = 0.81 are simulated. Gómez and Lagakos use plots, such as the one given in Figure 1, to
present the results and render the decision of whether to adopt a composite endpoint easier. We are
using them to study the different ARE values depending on the copula chosen (Figure 2).
It is clear in this situation that the primary endpoint E1 would have been recommended as primary
endpoint whenever HR2 > 0.9 (ARE< 1). Note that actual value was HR2 = 1.05. We also observe that
the ARE values decrease as ρ increases, and hence, the recommendation of using E1 is stronger as E1
and E2 are more correlated.
Figure 2 shows that the ARE values calculated under the eleven different copulas follow the same
pattern. There are 492 scenarios (97.6%) in which all copulas give the same recommendation on
whether to use E1 or E∗. Based on these scenarios, our conclusions summarizing the findings are the
following: i) use E∗ if HR2 < 0.9 and use E1 if HR2 > 0.9; ii) if HR2 = 0.9, there are 3 scenarios in which
it is more efficient to use E∗ and 48 scenarios in which it is more efficient to use E1. In the remaining 12
scenarios (2.38%), listed in Table 2, there is at least one copula that gives a different recommendation
than the others. All these scenarios correspond to weak correlations between T1 and T2 (ρ = 0.15 or
ρ = 0.25) and the benefits of using the composite endpoint over the relevant endpoint are marginal
(ARE values close to 1) and, as Gómez and Lagakos suggested, whenever ARE(Z∗,Z) < 1.1, E1 could
be used as well as the primary endpoint.
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Figure 2: ARE of using logrank test based on the composite endpoint (E∗) versus only using the relevant endpoint
(E1) for the case study given in Section 2.4. The plots are drawn for different copulas and using values
given in the study: p1 = 0.082, p2 = 0.09 and HR1 = 0.81; for different values of HR2 varying ρ
in the abscissae and for increasing marginal hazards (β1 = β2 = 2). FGM copula only allows weak
dependence (ρ < 1/3) and Tawn copula weak-moderate dependence (ρ < 0.587).
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Table 2: ARE of using logrank test based on the composite endpoint (E∗) versus only using the relevant endpoint
(E1) for the case study given in Section 2.4. 12 scenarios in which at least one of the copulas give different
recommendation than the others in using the composite endpoint (p1 = 0.082, p2 = 0.09, HR1 = 0.81
and HR2 = 0.9).
ARE values depending on the copula chosen
ρ β1 β2 Frank Gumbel Clayton Normal t Plackett Galambos Hüsler-Reiss t-EV Tawn FGM
0.15 0.5 0.5 1.02 1.04 0.99 1.02 1.00 1.02 1.04 1.04 1.04 1.03 1.03
0.15 1 0.5 1.01 1.02 0.98 1.01 0.99 1.01 1.03 1.03 1.02 1.02 1.02
0.15 1 1 1.02 1.04 0.99 1.02 1.00 1.02 1.04 1.04 1.04 1.03 1.03
0.15 2 0.5 1.01 1.02 0.97 1.00 0.99 1.00 1.02 1.02 1.02 1.01 1.01
0.15 2 1 1.01 1.02 0.98 1.01 0.99 1.01 1.03 1.03 1.02 1.02 1.02
0.15 2 2 1.02 1.04 0.99 1.02 1.00 1.02 1.04 1.04 1.04 1.03 1.03
0.25 0.5 0.5 0.98 1.00 0.94 0.97 0.97 0.98 1.00 1.00 1.00 1.00 0.99
0.25 0.5 1 1.00 1.02 0.95 0.99 0.98 0.99 1.02 1.02 1.02 1.01 1.01
0.25 0.5 2 1.02 1.04 0.97 1.00 1.00 1.01 1.03 1.04 1.03 1.03 1.02
0.25 1 1 0.98 1.00 0.94 0.97 0.97 0.98 1.00 1.00 1.00 1.00 0.99
0.25 1 2 0.99 1.01 0.95 0.99 0.98 0.99 1.02 1.02 1.02 1.01 1.01
0.25 2 2 0.98 1.00 0.94 0.97 0.97 0.98 1.00 1.00 1.00 1.00 0.99
3 simulation study
We have extended the ARE method to other families of copulas in order to allow different joint behav-
iors between T1 and T2. Illustration in Figure 2 has shown that the recommendation on whether to
use E1 or E∗ as the primary endpoint was, almost always, the same irrespective of the copula chosen.
We explore via a large simulation study how general is the pattern we have observed in this clinical
trial and whether or not the choice of the copula implies fundamental changes in the recommendation
based on the ARE value.
The study reproduces 145,152 situations (shown in Table 3) corresponding to:
(i) Several frequency situations for events E1 and E2 by taking probabilities p1 and p2 equal to 0.05,
0.1, 0.2, 0.3, 0.4 and 0.5.
(ii) The relative treatment effect on the relevant endpoint E1, given by the hazard ratio HR1, is set
to 0.5, 0.6, 0.7 and 0.8, indicating that the effect of the treatment is beneficial. Each hazard ratio
is combined with eight different relative treatment effects on the additional endpoint E2, namely
HR2, and set to 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 and 0.95.
(iii) Values for the shape parameters β1 and β2 of Weibull distribution are set to 0.5, 1 and 2 in order
to have decreasing, constant and increasing hazards, respectively.
(iv) A range of associations have been considered from weak (Spearman’s rank correlation ρ =
0.15, 0.25), through moderate (ρ = 0.35, 0.45) to strong (ρ = 0.55, 0.65, 0.75).
(v) Censoring case 1 where death is not among components of E1 neither among E2 and Censoring
case 3 where death is among the components of E1 but not of E2.
Results are very similar for both censoring cases and are only presented for Case 1. A brief de-
scriptive study of the ARE values is presented in Table 4 (72,576 simulated scenarios). ARE values for
Frank, Gumbel and Clayton copulas range between 0.03 and 267.3, 0.03 and 272.7 and 0.02 and 301.3,
respectively, with mean (standard deviation) equal to 4.95 (15.2), 5.08 (15.4) and 5.43 (16.9), respectively.
These results are similar for other copulas.
We have compared the ARE values pairwise for any 2 copulas and for each couple the following
measures of association have been evaluated: Pearson’s correlation coefficient ρ, Kendall’s τ and Lin’s
concordance correlation coefficient (CCC) (Lin, 1989; 2000). Table 5 gives these measures for the com-
parison of the ARE values obtained when Frank copula is used versus the ARE values obtained for any
of the other 10 copulas. We observe very large coefficients for all the copulas and all the measures. In
particular, Pearson’s correlation coefficient ρ and Lin’s concordance correlation coefficient (CCC) are
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Table 3: Values of the parameters β1, β2, p1, p2, HR1, HR2 and ρ that yield to the configurations used to
summarize the degree of agreement in adopting or not the composite endpoint depending on the choice
of the copula.
β1 0.5 1 2
β2 0.5 1 2
p1 0.05 0.1 0.2 0.3 0.4 0.5
p2 0.05 0.1 0.2 0.3 0.4 0.5
HR1 0.5 0.6 0.7 0.8
HR2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 0.95
ρ 0.15 0.25 0.35 0.45 0.55 0.65 0.75
Table 4: Descriptive analysis of the ARE value using Frank, Gumbel and Clayton copulas.
ARE using mean (SD) min Q1 median Q3 max
Frank copula 4.95 (15.2) 0.03 0.76 1.18 2.93 267.3
Gumbel copula 5.08 (15.4) 0.03 0.79 1.22 3.06 272.7
Clayton copula 5.43 (16.9) 0.02 0.86 1.21 3.12 301.3
Normal copula 5.13 (15.7) 0.03 0.80 1.22 3.06 280.4
t copula 5.33 (16.4) 0.03 0.84 1.24 3.13 283.2
Plackett copula 5.03 (15.5) 0.03 0.78 1.19 2.95 275.7
Galambos copula 5.08 (15.4) 0.03 0.79 1.23 3.07 272.4
Hüsler-Reiss copula 5.07 (15.4) 0.03 0.79 1.23 3.08 271.8
t-EV copula 5.08 (15.5) 0.03 0.79 1.22 3.06 273.1
Tawn copula* 5.16 (15.4) 0.06 0.81 1.29 3.21 264.1
FGM copula* 5.24 (15.2) 0.08 0.82 1.35 3.42 261.7
* Results for Tawn and FGM copulas are restricted to those scenarios in
which ρ < 0.587 (n=51,840) and ρ < 1/3 (n=20,736), respectively.
above 0.99 for all the comparisons while Kendall’s τ is a bit lower but above 0.92 in all the cases. Other
comparisons for other pairs of copulas yielded similar results, for instance the pair Gumbel-Clayton
has Pearson’s ρ=0.998, Kendall’s τ=0.932 and Lin’s CCC=0.994.
Scatter plots for the ARE values for any 2 copulas complement the above association measures.
These plots have been restricted to ARE values within the range [0, 2] because an ARE value = 1 draws
the line between recommending the relevant endpoint E1 or the composite endpoint E∗. Figure 3
shows three such plots for the comparisons Frank-Gumbel, Frank-Clayton and Gumbel-Clayton. We
clearly observe that the values obtained using Frank and Gumbel copulas are highly correlated, al-
though the values are, on average, slightly larger using Gumbel copula. The ARE values for the pair
Frank-Clayton are also correlated with larger variability than for the pair Frank-Gumbel. The compar-
ison Gumbel-Clayton is also reproduced showing a similar behavior to Frank-Clayton. Comparisons
to other copulas are similar to these ones and are omitted.
When it comes to the real application of the ARE method, and given the clear difficulty in having
to decide between one or other copula, it is of crucial importance to know how much agreement there
will be in the recommendation as a function of the copula chosen. With this in mind, we define the
degree of agreement between two copulas as the percentage of situations in which both copulas agree
in either recommending the use of the relevant endpoint (ARE 6 1) or recommending the composite
endpoint (ARE > 1). Based on our reproduced settings, we find a very high degree of agreement (see
Table 5). In all the comparisons the degree of agreement is larger than 94%, for instance, 98.0% for the
pair Frank-Gumbel, 94.7% for Frank-Clayton and 96.3% for Gumbel-Clayton.
We then study the discordant situations, that is, those scenarios yielding an ARE value with copula
C1 > 1 while an ARE value with copula C2 6 1, which would imply a different decision on which
primary endpoint to use. We restrict the results presented here to the most popular copulas: Frank,
Gumbel and Clayton (see Table 6) since the comparisons with the other copulas are similar to these
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Table 5: Comparison of the ARE values obtained using several families of copulas to Frank copula using Pearson’s
ρ, Kendall’s τ, Lin’s concordance correlation coefficient (CCC) and degree of agreement in recommend-
ing the main endpoint.
Copula Pearson’s ρ Kendall’s τ Lins’s CCC Agreement
Gumbel > 0.999 0.982 > 0.999 98.0%
Clayton 0.997 0.927 0.991 94.7%
Normal > 0.999 0.972 0.999 97.8%
t > 0.999 0.964 0.996 95.5%
Plackett > 0.999 0.984 > 0.999 98.8%
Galambos > 0.999 0.982 > 0.999 98.1%
Hüsler-Reiss > 0.999 0.981 > 0.999 98.1%
t-EV > 0.999 0.982 > 0.999 98.0%
Tawn* > 0.999 0.971 > 0.999 97.4%
FGM* > 0.999 0.997 > 0.999 99.9%
* Results for Tawn and FGM copulas are restricted to those scenarios
in which ρ < 0.587 (n=51,840) and ρ < 1/3 (n=20,736), respectively.
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Figure 3: Scatter plot of the pairs of values using Frank and Gumbel copulas, Frank and Clayton copulas and
Gumbel and Clayton copulas within the range [0, 2]. The line represents the situation in which both
values are the same.
ones. We observe that, mostly, the difference between the two ARE values is very small (medians
6 0.09). These situations are not worrisome because, when it comes to establishing statistical effi-
ciency guidelines, the advantage of one endpoint over the other is very slight in the vicinity of one,
and whenever 1 < ARE(Z∗,Z) < 1.1, the benefits of using the composite endpoint over the relevant
endpoint are marginal and, probably, too small to counteract the interpretational complications of a
composite endpoint (Gómez and Lagakos, 2013). Furthermore, ARE values in the vicinity of 1 would
imply, approximately, the same sample size whether E1 or E∗ is used.
Those discordant situations where the difference is large enough so the direction of the recommen-
dation would be reversed is lastly studied next. We first observe that the agreement between Frank
and Gumbel is extremely good with absolute differences at most of 0.14. For the pairs Frank-Clayton
and Gumbel-Clayton, there are respectively 1,138 (1.6%) and 617 (0.8%) discordant situations in which
the distance between the two ARE values is larger than 0.15. Most of those situations (1,088 and 554,
respectively) correspond to settings where the two relative treatment effects are very close (HR1 = HR2
or HR1 = HR2 − 0.1) and the relevant and the additional endpoints, T1 and T2, are moderate or highly
correlated (ρ > 0.35).
We end this Section summarizing the recommendation of when to choose the composite endpoint
as a function of the difference between the hazard ratios for the two endpoints, HR2 −HR1, and for
the following copulas: Frank, Gumbel and Clayton. Figure 4 provides, first, the percentage of cases
in which the composite endpoint should be used, and second, the percentage of cases in which there
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Table 6: Descriptive analysis, when there is not agreement between copulas C1 and C2 (ARE (C1)> 1 while
ARE (C2) 6 1), of the absolute difference between each pair of ARE values for the pairs of copulas
Frank-Gumbel, Frank-Clayton and Gumbel-Clayton.
Discordant cases n mean (SD) min Q1 median Q3 P95 max
|AREF −AREG| 1426 0.04 (0.03) 0.004 0.02 0.05 0.06 0.11 0.14
|AREF −AREC| 3812 0.11 (0.08) 0.001 0.04 0.09 0.17 0.27 0.36
|AREG −AREC| 2696 0.09 (0.07) 0.001 0.03 0.07 0.14 0.23 0.38
Figure 4: Percentage of situations in which the composite endpoint (CE) should be used for each copula and
percentage of cases in which there is agreement between the pair of copulas depending on the difference
between the hazard ratios of the relevant and the additional endpoints, HR1 and HR2
is agreement between the three pairs of copulas. Whenever the treatment has a larger beneficial effect
on the additional endpoint E2 than on the relevant endpoint E1, the composite endpoint is almost
always recommended irrespective of the copula chosen. If there is much larger beneficial effect on E1
than on E2 (HR2 −HR1 > 0.3), the recommendation of sticking to the relevant endpoint E1 is almost
always recommended for the three copulas chosen. However, if the hazard ratios of the relevant
and the additional endpoints are very close (0 6 HR2 −HR1 6 0.1), the degree of agreement between
Frank-Clayton and Gumbel-Clayton is in the order of 80.0%, hence the recommendation would heavily
depend on the copula chosen.
4 concluding remarks
The decision on which endpoint to choose as the primary endpoint for the analysis of the efficacy
of two treatments in a randomized clinical trial is addressed by Gómez and Lagakos (2013). Their
method is based on the behavior of the Asymptotic Relative Efficiency (ARE) of the logrank test for
the null hypothesis of no treatment effect observed in the composite endpoint versus the logrank test
of no treatment effect observed in one of the relevant components of the composite endpoint. Once a
copula has been chosen to specify the joint law between the time T1 to the relevant endpoint E1 and the
time T2 to the additional E2 endpoint, the computation of the ARE is possible from few anticipatable
parameters, such as the expected proportion of subjects experiencing the event in the control group
and the hazard ratios both for the relevant E1 and the additional E2 endpoints. Plots like those shown
in Figure 1 are proposed to derive recommendations without the need of anticipating the degree of
association between T1 and T2. This paper has extended the ARE method to other families of copulas
and has studied the effect that the copula has in the ARE value. The paper has as well discussed the
consequences that the choice of a copula has on the recommendation for the primary endpoint.
Firstly, it has been shown that the correlation and concordance between the ARE values for the
different copulas is very high, being this fact a first indication of the applicability of the ARE method.
Secondly, there is a high degree of agreement between the recommendation that the different copulas
would propose as to which endpoint to choose.
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It has also been demonstrated that, even though the computation of the ARE strongly relies on
the copula binding the marginals of T1 and T2, when it comes to recommending one endpoint over
the other, the particular choice of the copula is, almost always, irrelevant. Cases where it matters
correspond to similar values of the relative effect of treatment on the relevant and the additional
endpoints (HR1 and HR2 very close), yielding ARE values closer to 1. In those cases, the decision on
which endpoint to use has to be based on other grounds and, since the effect of the treatment is similar
in the relevant and additional endpoints, the choice of the endpoint has not big implications.
Despite those few situations in which the agreement is lower, we conclude that the ARE method
is robust to the choice of the copula when restricted to Frank, Gumbel, Clayton, Farlie-Gumbel-
Morgenstern, Normal, t, Plackett, Galambos, Hüsler-Reiss, Tawn and t-EV families. Therefore, this
methodology is widely applicable and the computation of the ARE with the purpose of choosing the
primary endpoint can be, in general, restricted to one of the above given copulas.
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appendix
A.1. Frank, Gumbel and Clayton copulas
The expression of Frank’s copula is given by
CF(u, v; θ) =
−1
θ
log
(
1+
(e−θu − 1)(e−θv − 1)
e−θ − 1
)
(5)
where the dependence parameter may assume any real value, (θ ∈ (−∞,∞)\{0}), and the limiting case
θ → 0 corresponds to the independence between T1 and T2. Frank copula is a symmetric copula that
allows both negative and positive dependence between variables and exhibits the same dependence
in the left and in the right tail. A two-way scatter diagram of realizations from simulated drawings
from copulas illustrates tail dependences in a bivariate framework (see Figure 5). Frank copula is best
suited for applications in which tail dependence is relatively weak, as it is shown in the plot.
Gumbel copula is given by
CG(u, v; θ) = exp
(
−[(− log(u))θ + (− log(v))θ]1/θ
)
(6)
where the dependence parameter may assume any real number greater or equal than 1, (θ ∈ [1,∞)).
Gumbel copula only allows positive dependence and exhibits relatively weak left tail dependence and
strong right tail dependence (Trivedi and Zimmer, 2007) (see Figure 5). Gumbel is an appropriate
choice for the joint behavior when the two endpoints are likely to simultaneously realize upper tail
values.
Clayton copula is given by
CC(u, v; θ) = max{[u−θ + v−θ − 1]−1/θ, 0} (7)
where the dependence parameter may assume any real number larger or equal than -1 (θ ∈ [−1,∞)\{0}).
Clayton copula only accounts for positive dependence and exhibits strong left tail dependence and rel-
atively weak right tail dependence (Trivedi and Zimmer, 2007) (see Figure 5). Clayton copula is best
suited for applications in which the two outcomes are likely to experience low values together.
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Figure 5: Simulation of 1500 samples of C(u, v; θ) using Frank, Gumbel and Clayton copulas. The dependence pa-
rameter θ has been set such that Spearman’s ρ = 0.8 for the three copulas. The conditional distribution
method (Nelsen, 1999) has been used to generate these samples.
These 3 plots in Figure 5 show how different the dependence structures might be even with similar
degrees of dependence reinforcing the need of an extension of the ARE method to other families of
copulas.
A.1.1. Survival and density functions of T∗
1. Frank copula
If Frank copula CF presented in (5) is used, the joint survival function for (T1, T2) in group j
(j = 0, 1) is given by
S
(j)
(1,2)(t1, t2; θ) =
−1
θ
log
(
1+
(e−θS
(j)
1 (t1) − 1)(e−θS
(j)
2 (t2) − 1)
e−θ − 1
)
.
It follows from (4) that
f
(j)
∗ (t; θ) =
1
e−θ−1
[
e−θS
(j)
1 (t)(e−θS
(j)
2 (t) − 1)
e
−θS
(j)
(1,2)(t,t;θ)
f
(j)
1 (t) +
e−θS
(j)
2 (t)(e−θS
(j)
1 (t) − 1)
e
−θS
(j)
(1,2)(t,t;θ)
f
(j)
2 (t)
]
.
2. Gumbel copula
Using Gumbel copula CG given in (6), it follows from (3) that
S
(j)
∗ (t; θ) = S
(j)
1 (t) + S
(j)
2 (t) − 1+ exp
(
−
[
(− log(1− S(j)1 (t)))
θ + (− log(1− S(j)2 (t)))
θ
]1/θ)
,
and from (4) that
f
(j)
∗ (t; θ) = f
(j)
1 (t) + f
(j)
2 (t) − exp
(
−
[
(− log(1− S(j)1 (t)))
θ + (− log(1− S(j)2 (t)))
θ
]1/θ)
[
(− log(1− S(j)1 (t)))
θ + (− log(1− S(j)2 (t)))
θ
] 1−θ
θ(
(− log(1− S(j)1 (t)))
θ−1 f
(j)
1 (t)
1− S
(j)
1 (t)
+ (− log(1− S(j)2 (t)))
θ−1 f
(j)
2 (t)
1− S
(j)
2 (t)
)
3. Clayton copula
Using Clayton copula CC given in (7), it follows from (3) that
S
(j)
∗ (t; θ) = S
(j)
1 (t) + S
(j)
2 (t) − 1+ [(1− S
(j)
1 (t))
−θ + (1− S
(j)
2 (t))
−θ − 1]−1/θ
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and from (4) that
f
(j)
∗ (t; θ) = f
(j)
1 (t) + f
(j)
2 (t) − [(1− S
(j)
1 (t))
−θ + (1− S
(j)
2 (t))
−θ(j) − 1]−
1+θ
θ(
(1− S
(j)
1 (t))
−(1+θ)f
(j)
1 (t) + (1− S
(j)
2 (t))
−(1+θ)f
(j)
2 (t)
)
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